AVACTA GROUP PLC - Interim Results

Avacta guides to five clinical/data catalysts within eight weeks, with AVA6103's early PK and safety closely matching preclinical predictions and beating Enhertu comparators.

• Next-gen PDC platform: Avacta's precision mask-and-release peptide drug conjugates use FAP (fibroblast activation protein), abundant in ~90% of solid tumor stroma, to selectively cleave and release payloads in tumors, sparing healthy tissue.
• AVA6103 dose escalation: Four dose levels completed across six indications (gastric, colorectal, cervical, small cell lung, HR+ breast, pancreatic); first three cohorts show no neutropenia despite dosing 50% above exatecan's historical MTD.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.